Daniel Mullins, PhD: How Biosimilars Are Impacting Costs

Transcript

Biosimilars are a real game-changer. In the same way that we've seen a reduction in price as we see traditional medicines going to branded, we're seeing the same thing with biosimilars.

If you would have asked me what am I potentially worried about, if you look back to the literature, when generics first came out to the market in the more expedited role, there was a generic drug scandal, and if anything were to happen where there were a biosimilar that was used that we found out really wasn't as good as the originator biologic, that could set biologics back.

But short of that, I really do believe that this is going to be good for the American public.